Biophytis S.A.

AGM Information • Aug 8, 2019

Biophytis – Shareholders Approve All Resolutions at the Extraordinary General Meeting held on August 8, 2019

Paris, France, August 8, 2019, - Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of novel treatments for age-related diseases, today announces that shareholders have approved all of the resolutions proposed during the Extraordinary General Meeting.

Biophytis' shareholders met in Paris, France for the Extraordinary General Meeting on August 8, 2019. The shareholders present or represented taking part in the vote altogether owned 3,086,271 shares, reaching a quorum of 23.1%, and 4,680,287 voting rights.

The approved resolutions include:

• granting the delegation of powers to the board of directors for the purpose of funding the Company's operations by issuing ordinary shares and/or securities up to €7,000,000 for the maximum nominal amount of ordinary shares to be issued and €40,000,000 for the maximum nominal amount of debt securities to be issued and
• the authorizations to be granted to the board of directors in order to issue equity incentive instruments.

About Biophytis

Biophytis is a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Our therapeutic approach is aimed at targeting and activating key biological resilience pathways that can protect against and counteract the effects of the multiple biological and environmental stresses that lead to agerelated diseases.

****

Our lead drug candidate, Sarconeos (BIO101), is an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD). Our preclinical drug candidate, Macuneos (BIO201), is an orally administered small molecule in development for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease.

Biophytis is headquartered in Paris, France, and has offices in Cambridge, Massachusetts. The Company's ordinary shares are listed on Euronext Growth Paris (Ticker: ALBPS - ISIN: FR0012816825). For more information please visit www.biophytis.com .

Disclaimer

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to securities of Biophytis in any country. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, Biophytis undertakes no obligation to update or revise the information contained in this press release. This press release has been prepared in both French and English. In the event of any differences between the two texts, the French language version shall prevail.

Press Release

Biophytis Investor Relations Contact

Daniel Schneiderman, CFO dan.schneiderman@biophytis.com Tel: +1 (857) 220-9720

U.S. Media Contact

LifeSci Public Relations Cherilyn Cecchini, M.D. ccecchini@lifescipublicrelations.com Tel: +1 (646) 876-5196

Europe Media Contact

Citigate Dewe Rogerson Quentin Dussart / Sylvie Berrebi / Nathaniel Dahan biophytis@citigatedewerogerson.com Tel: +33 (0)1 55 30 70 91 / +44 (0)20 76389571

Source: Biophytis